ADMA Biologics Files 8-K: Board & Compensation Updates

TL;DR

ADMA Biologics filed an 8-K on 12/30/24 covering board changes and executive pay.

AI Summary

On December 30, 2024, ADMA Biologics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also includes financial statements and exhibits, indicating ongoing corporate governance and financial reporting activities for the company.

Why It Matters

This filing provides insight into the company's leadership structure and executive pay, which can influence investor confidence and strategic direction.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain significant negative news.

Key Players & Entities

• ADMA BIOLOGICS, INC. (company) — Registrant
• December 30, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 465 State Route 17, Ramsey, New Jersey 07446 (address) — Principal executive offices

FAQ

Filing Documents

• ef20040947_8k.htm (8-K) — 29KB
• 0001140361-25-000073.txt ( ) — 161KB
• adma-20241230.xsd (EX-101.SCH) — 4KB
• adma-20241230_lab.xml (EX-101.LAB) — 21KB
• adma-20241230_pre.xml (EX-101.PRE) — 16KB
• ef20040947_8k_htm.xml (XML) — 4KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 30, 2024, the Board of Directors (the "Board") of ADMA Biologics, Inc. (the "Company") appointed Eduardo Rene Salas to serve on the Board as a Class I director with a term expiring at the Company's 2026 annual meeting of stockholders. Mr. Salas has extensive experience as a financial executive serving both publicly traded and privately-owned companies. Since 2022, Mr. Salas has served on the audit committee of Intra-Cellular Therapies, Inc. From 2021 to 2023, Mr. Salas served as the lead independent director and audit committee chair of Embody, Inc., a private company that was acquired by Zimmer Biomet Holdings, Inc. From 2020 to 2022, Mr. Salas served as Chief Financial Officer of Wellstat Therapeutics, LLC, a company focused on the development and distribution of pharmaceutical drugs. Prior to his tenure at Wellstat, Mr. Salas served as a senior client serving audit partner of Ernst & Young LLP ("EY") from 2002 until retirement in 2019. Mr. Salas has a B.A. in business administration from The University of Texas at San Antonio. During his time at EY, Mr. Salas completed Strategic Leadership programs at Harvard Business School and at Northwestern University, Kellogg School of Management. There is no arrangement or understanding between Mr. Salas and any other person pursuant to which Mr. Salas was selected to serve as a director of the Company, nor is Mr. Salas a party to any transactions required to be disclosed under Item 404(a) of Regulation S-K involving the Company. As a non-employee director, Mr. Salas is eligible to participate in the ADMA Biologics, Inc. 2022 Equity Compensation Plan. For his service on the Board, Mr. Salas will receive compensation in accordance with the Company's general policies for compensation of non-employee directors, including, without limitation, an initial gra

01

Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. January 2, 2025 ADMA Biologics, Inc. By: /s/ Adam S. Grossman Name: Adam S. Grossman Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR